Historic decision from the European Commission grants 120 million women direct access to ellaOne® emergency contraceptive across the European Union.
Ketoconazole HRA® Granted European Marketing Authorisation as an Orphan Drug for the Treatment of Endogenous Cushing’s Syndrome
Landmark recommendation from EMA paves the way for access without prescription to the ellaOne® morning-after pill across Europe in 2015.
HRA Pharma Acquires a Novel Ovarian Cancer Immunotherapy from Pantarhei Bioscience
HRA Pharma Receives European CHMP Positive Opinion for Ketoconazole in the Treatment of Endogenous Cushing’s Syndrome